Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Поддерживающая терапия немелкоклеточного рака легкого
Поддерживающая терапия немелкоклеточного рака легкого
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Представлены данные о современном состоянии проблемы поддерживающей терапии немелкоклеточного рака легкого. Предпринята попытка определить целевую группу больных, где поддерживающее лечение имеет максимальный успех.
Ключевые слова: немелкоклеточный рак легкого, поддерживающее лечение, пеметрексед, гемцитабин, ингибиторы EGFR.
Key words: non-small cell lung cancer, maintenance treatment, pemetrexed, gemcitabine, EGFR inhibitors.
Ключевые слова: немелкоклеточный рак легкого, поддерживающее лечение, пеметрексед, гемцитабин, ингибиторы EGFR.
________________________________________________
Key words: non-small cell lung cancer, maintenance treatment, pemetrexed, gemcitabine, EGFR inhibitors.
Полный текст
Список литературы
1. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21: 2933–9.
2. Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitab- ine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155–63.
3. Perol M, Chouaid C, Milleron BJ et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010; 28 (Suppl. Abstr. 7507).
4. Belani CP, Waterhouse DM, Ghazal H et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carbo- platin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: (Suppl. Abstr. 7506).
5. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. www.thelancet.com/oncology
6. Paz-Ares L, de Marinis F, Dediu M et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30 (Suppl. Abstr. LBA7507).
7. Barlesi F, de Castro J, Dvornichenko V et al. AVAPERL (MO22089): final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (1L) bev-cisplatin (cis)-pem treatment (Tx). Eur J Cancer 2011; 47 (Abstract 34LBA): 16.
8. Azzoli CG, Baker S, Temin S et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 2009; 27: 6251–66; Mok TS, Ramalingam SS. Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 2009; 115: 5143–54.
9. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591–8.
10. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432–40.
11. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521–9.
12. Miller VA, O'Connor P, Soh C et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 (Suppl. Abstr. LBA8002): 18s.
13. Kabbinavar FF, Miller VA, Johnson BE et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: 15s (Suppl. Abstr. 7526).
14. Takeda K, Hida T, Sato T et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WTOG0203). J Clin Oncol 2010; 28: 753–60.
15. Zhang L, Shenglin M, Song X et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 2011; 29: S7511.
16. Gaafar RM, Surmont V, Scagliotti G et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (Pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). Eur J Cancer 2011; 47: 2331–40.
17. Cohen MH, Johnson JR, Chattopadhyay S et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010; 15 (12): 1344–51; Cohen MH, Cortazar P, Justice R et al. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010; 15 (12): 1352–8.
18. Behera M, Owonikoko TK, Chen Z et al. Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis. J Clin Oncol 2011; 29 (Suppl. Abstr. 7553).
2. Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitab- ine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155–63.
3. Perol M, Chouaid C, Milleron BJ et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010; 28 (Suppl. Abstr. 7507).
4. Belani CP, Waterhouse DM, Ghazal H et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carbo- platin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: (Suppl. Abstr. 7506).
5. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. www.thelancet.com/oncology
6. Paz-Ares L, de Marinis F, Dediu M et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30 (Suppl. Abstr. LBA7507).
7. Barlesi F, de Castro J, Dvornichenko V et al. AVAPERL (MO22089): final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (1L) bev-cisplatin (cis)-pem treatment (Tx). Eur J Cancer 2011; 47 (Abstract 34LBA): 16.
8. Azzoli CG, Baker S, Temin S et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 2009; 27: 6251–66; Mok TS, Ramalingam SS. Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 2009; 115: 5143–54.
9. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591–8.
10. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432–40.
11. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521–9.
12. Miller VA, O'Connor P, Soh C et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 (Suppl. Abstr. LBA8002): 18s.
13. Kabbinavar FF, Miller VA, Johnson BE et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: 15s (Suppl. Abstr. 7526).
14. Takeda K, Hida T, Sato T et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WTOG0203). J Clin Oncol 2010; 28: 753–60.
15. Zhang L, Shenglin M, Song X et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 2011; 29: S7511.
16. Gaafar RM, Surmont V, Scagliotti G et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (Pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). Eur J Cancer 2011; 47: 2331–40.
17. Cohen MH, Johnson JR, Chattopadhyay S et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010; 15 (12): 1344–51; Cohen MH, Cortazar P, Justice R et al. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010; 15 (12): 1352–8.
18. Behera M, Owonikoko TK, Chen Z et al. Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis. J Clin Oncol 2011; 29 (Suppl. Abstr. 7553).
Авторы
С.Л.Гуторов, Е.И.Борисова
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.